Fig. 1: The efficacy of mCD19 CAR-T cell on subcutaneous lymphoma and the distribution of macrophages in TME. | Cell Death & Disease

Fig. 1: The efficacy of mCD19 CAR-T cell on subcutaneous lymphoma and the distribution of macrophages in TME.

From: The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma/leukemia

Fig. 1

A Subcutaneously seeded lymphoma in mice with or without CD19 CAR-T cell treatment. B The changes in tumor volume were quantified and subjected to statistical analysis. Statistical analyses were performed using the two-way ANOVA. C Tumors were excised and their weights were recorded. D Proportions of CD3+ T cells, CD11b+ myeloid cells, and F4/80+CD11b+ macrophages within tumor tissues. E Representative images depicting whole-slice scans for immunofluorescence in different experimental groups (magnification ×10). F Immunofluorescence staining using F4/80 antibodies was performed on tumor and adjacent tissue sections to identify macrophages (magnification ×200). The white dashed lines were employed to demarcate the tumor tissues from the adjacent tissues. G Statistical analysis were done to calculate the infiltrated macrophages. Pooled data from 3 fields (magnification ×200; n = 3). The Mean fluorescence intensity (MFI) of F4/80+ macrophages was quantified, followed by statistical analysis. (C, D, and G) were statistically analyzed using unpaired t-test. *P < 0.05, **P < 0.01, **** P < 0.0001.

Back to article page